- Home
- ZURA vs AVIR Comparison
ZURA vs AVIR Comparison
Compare ZURA & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- AVIR
- Stock Information
- Founded
- ZURA 2022
- AVIR 2012
- Country
- ZURA United States
- AVIR United States
- Employees
- ZURA N/A
- AVIR N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- ZURA Health Care
- AVIR Health Care
- Exchange
- ZURA Nasdaq
- AVIR Nasdaq
- Market Cap
- ZURA 69.9M
- AVIR 273.0M
- IPO Year
- ZURA N/A
- AVIR 2020
- Fundamental
- Price
- ZURA $1.91
- AVIR $3.39
- Analyst Decision
- ZURA Buy
- AVIR Hold
- Analyst Count
- ZURA 7
- AVIR 1
- Target Price
- ZURA $14.33
- AVIR $6.00
- AVG Volume (30 Days)
- ZURA 1.2M
- AVIR 413.2K
- Earning Date
- ZURA 08-08-2025
- AVIR 08-06-2025
- Dividend Yield
- ZURA N/A
- AVIR N/A
- EPS Growth
- ZURA N/A
- AVIR N/A
- EPS
- ZURA N/A
- AVIR N/A
- Revenue
- ZURA N/A
- AVIR N/A
- Revenue This Year
- ZURA N/A
- AVIR N/A
- Revenue Next Year
- ZURA N/A
- AVIR N/A
- P/E Ratio
- ZURA N/A
- AVIR N/A
- Revenue Growth
- ZURA N/A
- AVIR N/A
- 52 Week Low
- ZURA $0.97
- AVIR $2.46
- 52 Week High
- ZURA $5.07
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- ZURA 77.68
- AVIR 51.38
- Support Level
- ZURA $1.26
- AVIR $3.43
- Resistance Level
- ZURA $1.45
- AVIR $3.83
- Average True Range (ATR)
- ZURA 0.16
- AVIR 0.14
- MACD
- ZURA 0.08
- AVIR -0.04
- Stochastic Oscillator
- ZURA 77.12
- AVIR 15.19
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).